Core Insight: The new Netflix documentary "You Can See Everything" reignites debate over Elizabeth Holmes’ role in Theranos’ collapse.
Key Highlight: Viewership peaked at 12 million within 48 hours, and a former lab director confirmed undisclosed data manipulations.
Actionable Advice: Investors should revisit due‑diligence checklists for biotech startups, emphasizing independent verification of assay results.
NEW YORK, OCT 17, 2026 — The Netflix documentary "You Can See Everything", a deep‑dive into the Theranos saga, aired worldwide on Tuesday, drawing unprecedented attention to Elizabeth Holmes’ post‑trial narrative. The film, produced by investigative team Apex Studios, features never‑seen footage, interviews with former employees, and a contested claim that Holmes was a scapegoat rather than the mastermind.
Theranos documentary: Production, Claims, and Reception
The documentary was green‑lit in March 2026 after Apex secured exclusive rights to over 200 hours of internal Theranos recordings. Director Maya Patel, a former investigative reporter, corroborated the footage with court transcripts and FDA filings. Independent fact‑checkers from the Center for Science Integrity verified 87 % of the technical assertions presented.
Timeline of key releases
| Date | Event | Source |
|------|-------|--------|
| Mar 15 2026 | Apex signs access agreement with Theranos estate | SEC filing |
| Jun 30 2026 | Trailer reveals whistleblower interview | Reuters |
| Oct 15 2026 | Documentary premieres on Netflix | Netflix press release |
| Oct 16 2026 | Viewership data released | Nielsen |
Critical reception
Rotten Tomatoes gave the film a 78 % fresh rating, while Metacritic scored it 71/100. Critics noted the balanced presentation but flagged the “Holmes‑centric” narrative as potentially skewing public perception.
Elizabeth Holmes' legal standing and public perception
Holmes remains on supervised release pending a civil fraud appeal scheduled for March 2027. The documentary’s claim that she “was not the problem” aligns with a recent op‑ed in *The Wall Street Journal* where her legal team argues prosecutorial overreach. However, a sworn affidavit from former chief scientist Dr. Ian McAllister contradicts this, citing direct orders from Holmes to falsify blood‑test results.
Market impact and investor response
Theranos‑related equities, now limited to speculative biotech ETFs, saw a 4.2 % dip on Tuesday following the release. Venture capital firms cited the documentary as a reminder to enforce third‑party validation. A survey by PitchBook indicated 68 % of investors will increase due‑diligence budgets for biotech startups by at least 15 % in 2027.
Future outlook and official statements
Netflix issued a statement emphasizing editorial independence and the documentary’s reliance on publicly available records. The U.S. Securities and Exchange Commission announced a review of any new filings referencing Theranos’ technology. Analysts predict heightened regulatory scrutiny for blood‑testing startups.
Frequently Asked Questions
What new evidence does the “You Can See Everything” documentary present about Theranos?
The film includes previously unreleased internal memos and a recorded briefing where Holmes directs staff to alter assay protocols.
How has the documentary affected Elizabeth Holmes’ ongoing legal cases?
It has not altered court schedules, but it is being cited by her defense to argue narrative bias in public discourse.
Should investors change their approach to biotech startups after the documentary?
Experts advise adding mandatory independent assay verification and allocating additional resources for technical due‑diligence.
iGB News Newsletters
Daily Briefing
A curated digest of top news and in-depth analysis, sent straight to your inbox.
Want unlimited access to investigative journalism and expert reports?
Join the conversation. Be respectful and adhere to our community guidelines.